Cited by 67Sarcoma Diagnosis and TreatmentGenomic variations and chromosomal abnormalitiesChromatin Remodeling and Cancer

High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: a cytogenomic microarray analysis of 47 cases

Ricciotti, Robert W., Baraff, Aaron J., Jour, George, Kyriss, McKenna, Wu, Yu, Liu, Yuhua, Li, Shao-Chun, Hoch, Benjamin +1 more·2017·Cancer Genetics

Abstract

Dedifferentiated liposarcoma (DDLS) is characterized at the molecular level by amplification of genes within 12q13-15 including MDM2 and CDK4. However, other than FNCLCC grade, prognostic markers are limited. We aim to identify molecular prognostic markers for DDLS to help risk stratify patients. To this end, we studied 49 cases of DDLS in our institutional archives and performed cytogenomic microarray analysis on 47 cases. Gene copy numbers for 12 loci were evaluated and correlated with outcome data retrieved from our institutional electronic medical records. Using cut point analysis and comparison of Kaplan-Meier survival curves by log rank tests, high amplification levels of MDM2 (>38 copies) and CDK4 (>30 copies) correlated with decreased disease free survival (DFS) (P = .0168 and 0.0169 respectively) and disease specific survival (DSS) (P = .0082 and 0.0140 respectively). Additionally, MDM2 and CDK4 showed evidence of a synergistic effect so that each additional copy of one enhances the effect on prognosis of each additional copy of the other for decreased DFS (P = .0227, 0.1% hazard). High amplification of JUN (>16 copies) also correlated with decreased DFS (P = .0217), but not DSS. The presence of copy number alteration at 3q29 correlated with decreased DSS (P = .0192). The presence of >10 mitoses per 10 high power fields and FNCLCC grade 3 also correlated with decreased DFS (P = .0310 and 0.0254 respectively). MDM2 and CDK4 gene amplification levels, along with JUN amplification and copy alterations at 3q29, can be utilized for predicting outcome in patients with DDLS.

Integrity signals

Registry

Crossref · 10.1016/j.cancergen.2017.09.005

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

3 of the 41 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Ricciotti, R. W., Baraff, A. J., Jour, G., Kyriss, M., Wu, Y., Liu, Y., Li, S.-C., Hoch, B., & Liu, Y. J.
Affiliations
  • University of Washington (US)
  • Cooper University Hospital (US)
Corresponding author
  • Hoch, Benjamin
  • Liu, Yajuan J.
Venue
Cancer Genetics
Publisher
Elsevier BV
Published
2017-12
Volume
218-219
Pages
69-80
ISSN
2210-7762 (ISSN-L)
OpenAlex
W2756552974
Cited by
67
References
41
Citations by year
2026: 5 · 2025: 9 · 2024: 9 · 2023: 9 · 2022: 6 · 2021: 7 · 2020: 6 · 2019: 9 · 2018: 7
FWCI
4.97
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Genetics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
dedifferentiated liposarcoma, MDM2 amplification, CDK4 amplification, prognostic factors, disease-free survival, disease-specific survival, FNCLCC grade, mitotic count
MeSH terms
Adult, Aged, Aged, 80 and over, Cell Differentiation, Female, Follow-Up Studies, Gene Amplification, Humans, Liposarcoma, Male, Middle Aged, Neoplasm Staging, Prognosis, Retrospective Studies, Biomarkers, Tumor, In Situ Hybridization, Fluorescence, Gene Dosage, Microarray Analysis, Cyclin-Dependent Kinase 4, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review